Financial Express reports that India’s Dr. Reddy’s Laboratories, based in the southern city of Hyderabad, disclosed plans to expand in the U.S. and emerging markets this year; widen its reach in Europe; invest in new drugs that offer higher margins such as complex generics, biosimilars and proprietary products; and promote stronger research and development for developing finished dosages.
G.V. Prasad, co-chairman and chief executive of Dr. Reddy’s Laboratories told the Financial Express, “The U.S. market is so big that there is no equivalent alternative. We just have to get stronger in the U.S., resolve our issues, build a pipeline and be more innovative to drive growth.”
Currently the company has six biosimilar products that are yet to be launched. Another five more are in the clinical development pipeline between now and March 2020. Apart from this, its proprietary product portfolio includes drugs for skin conditions and the central nervous system. It hopes to file two new drug applications every year and expects a five- to ten-year exclusivity for some of the products. In April, Dr. Reddy’s had acquired 28 brands from the UCB portfolio in India to expand its footprint in therapy segments such as dermatology, respiratory and pediatrics, and boost its domestic revenues.
Last updated: December 26th, 2025
